1-6 of 6
Jeffrey E. Lancet
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Clinical Trials & Observations
Rami S. Komrokji, Luis E. Aguirre, Najla H. Al Ali, Onyee Chan, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3677–3679.
https://doi.org/10.1182/bloodadvances.2023009781
Published: 2023
Journal Articles

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

Clinical Trials & Observations
Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Stuart L. Goldberg, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet
Journal: Blood Advances
Blood Adv (2022) 6 (17): 4989–4993.
https://doi.org/10.1182/bloodadvances.2021006468
Published: 2022
Includes: Supplemental data
Journal Articles

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Clinical Trials & Observations
Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes, Jeffrey E. Lancet
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1719–1728.
https://doi.org/10.1182/bloodadvances.2020003510
Published: 2021
Includes: Supplemental data
Journal Articles

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Clinical Trials & Observations
Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun, Najla Al Ali, Onyee Chan, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Eric Padron, Alan F. List, David A. Sallman
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1017–1028.
https://doi.org/10.1182/bloodadvances.2020003508
Published: 2021
Includes: Supplemental data
Journal Articles

Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant

Clinical Trials & Observations
Seongseok Yun, Onyee Chan, Daniel Kerr, Nicole D. Vincelette, Afshan Idrees, Qianxing Mo, Kendra Sweet, Jeffrey E. Lancet, Mohamed A. Kharfan-Dabaja, Ling Zhang, Lubomir Sokol
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3435–3442.
https://doi.org/10.1182/bloodadvances.2020001875
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

Clinical Trials & Observations
Jeffrey E. Lancet, Anna B. Moseley, Steven E. Coutre, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1683–1689.
https://doi.org/10.1182/bloodadvances.2019001278
Published: 2020